



Contact:  
CCG Elite Investor Relations  
Crocker Coulson, President  
Phone: +1-646-213-1915 (New York)  
E-mail: crocker.coulson@ccgir.com

*For Immediate Release*

## **China-Biotics, Inc. Launches English / Chinese Corporate and Investor Relations Web Site**

**Shanghai, China – January 30, 2008** – China-Biotics, Inc. (OTC BB: CHBT) (“China-Biotics”, “the Company”), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced it has launched a new bilingual corporate Web site under the domain name of <http://www.chn-biotics.com>.

The new Web site was created to strengthen communication and branding efforts with investors, customers and business partners. The site provides key information on China-Biotics, including corporate, industry and product information, corporate news, and important investor information such as access to SEC filings, investor presentations and earnings conference call webcasts. The Web site was designed in both English and Chinese by CCG Elite Investor Relations, China-Biotics’ investor relations agency.

“We are excited to launch our new Web site as we strive to improve communication with customers and investors,” said Mr. Jinan Song, Chairman and Chief Executive Officer of China-Biotics. “This valuable tool will enable us to educate consumers and investors about the growing importance of probiotics in both the Chinese and global markets. The site will also help us to deliver on our commitment to transparency as a U.S. publicly traded company.”

### **About China-Biotics, Inc.**

Headquartered in Shanghai, China-Biotics, Inc. (“China-Biotics”, “the Company”) was founded in 1999 and is one of China’s largest suppliers of probiotics. Probiotics are beneficial live bacteria used as dietary supplements and food additives to improve intestinal health and digestion. The Company’s product portfolio contains live microbials made with proprietary technology. Currently, these products are sold over-the-counter under the “Shining” brand through large distributors to more than 1,000 pharmacies and

100 supermarkets in Shanghai, Jiangsu and Zhejiang. Shining is one of the most recognized brands in Shanghai. China-Biotics plans to expand its retail sales to other major cities in China and will launch 300 Shining brand logistic centers in these cities during the next two years. The Company's flagship product, "Shining Essence", has been a profit driver since its launch in April 2001. There is a significant demand for probiotics for use in the bulk additive market, which is currently met by imports. China-Biotics is building a new plant which will increase its production capacity manifolds to capture this market. For more information, please visit <http://www.chn-biotics.com>

*Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such factors include, but are not limited to, the Company's ability to market existing and new products, ability to access to capital for expansion, and changes from anticipated levels of sales, future national or regional economic and competitive conditions, changes in relationships with customers, dependence on its flagship product profits and other factors detailed from time to time in the Company's filings with the United States Securities and Exchange Commission and other regulatory authorities. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.*

###